A number of other equities research analysts have also weighed in on GSK. Zacks Investment Research lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Wednesday, January 10th. ValuEngine lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Sunday, December 31st. Investec lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Monday, November 6th. Bank of America lowered shares of GlaxoSmithKline from a buy rating to a neutral rating in a research note on Thursday, October 26th. Finally, Cowen set a $38.00 target price on shares of GlaxoSmithKline and gave the company a hold rating in a research note on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $38.57.
Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.66 during trading on Thursday, reaching $37.50. 4,989,600 shares of the company’s stock were exchanged, compared to its average volume of 5,400,000. The company has a market cap of $92,080.00, a price-to-earnings ratio of 28.85, a PEG ratio of 2.15 and a beta of 0.97. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.
The business also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Stockholders of record on Friday, November 10th were paid a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.37%. GlaxoSmithKline’s payout ratio is presently 156.92%.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealthcare Advisory Partners LLC lifted its position in GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the period. FTB Advisors Inc. lifted its position in GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares during the period. Advisory Services Network LLC lifted its position in GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares during the period. Quadrant Capital Group LLC lifted its position in GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares during the period. Finally, Coastline Trust Co purchased a new position in GlaxoSmithKline during the 2nd quarter valued at about $202,000. 9.80% of the stock is owned by institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.